<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04608448</url>
  </required_header>
  <id_info>
    <org_study_id>HSC20200720H</org_study_id>
    <secondary_id>1R21AG068731-01</secondary_id>
    <nct_id>NCT04608448</nct_id>
  </id_info>
  <brief_title>Topical-RAPA Use in Inflammation Reversal and Re-setting the Epigenetic Clock</brief_title>
  <acronym>Topical-RAPA</acronym>
  <official_title>An Innovative Proof-of-concept Approach to Identify Age-modulating Drugs Capable of Reversing Inflammation and Re-setting the Epigenetic Clock (Topical-RAPA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center at San Antonio</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Texas Health Science Center at San Antonio</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Topical Rapamycin ointment will be applied to participant forearms to test whether epigenetic&#xD;
      changes in the skin are elicited.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rapamycin 8% ointment will be applied topically to one of the participant's forearms and&#xD;
      matching placebo to the opposite forearm daily for a total of 6 months. After consenting,&#xD;
      screening and randomization of arms, the participants will be monitored at monthly visits&#xD;
      until study completion.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 28, 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants will be their own control, either right or left arm will be randomized to treatment or placebo.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Randomization will be performed by the compounding pharmacy. Ointment dispensers will be color-coded for left and right arm for each subject.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in epigenetic markers</measure>
    <time_frame>6 months</time_frame>
    <description>A set of DNA methylation marks that correlate with chronological age will be used to measure rejuvenation of the &quot;epigenetic clock&quot; due to drug treatment compared to placebo. Using Illumina EPIC arrays, CpG methylation will be assessed and then the predicted age, based on the combined methylation at the set of 391 marks (the &quot;epigenetic clock&quot; as defined by Dr. Steven Horvath, UCLA), will be determined.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in inflammatory markers</measure>
    <time_frame>6 months</time_frame>
    <description>A measure of inflammatory markers will include analytes that are affected either by aging or oral rapamycin. Inflammatory markers are measured using Enzyme-Linked Immuno-Sorbant Assays (ELISA). The markers to be measured are CRP and IL-6.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Aging</condition>
  <condition>Epigenetics</condition>
  <condition>Inflammatory Mediators</condition>
  <arm_group>
    <arm_group_label>Topical Rapamycin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ointment is applied to a color coded area on the subject forearm daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo ointment is applied to a color coded area on the subject forearm daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rapamycin Topical Ointment</intervention_name>
    <description>8% topical rapamycin ointment</description>
    <arm_group_label>Topical Rapamycin</arm_group_label>
    <other_name>Sirolimus Topical Ointment</other_name>
    <other_name>RAPA Topical Ointment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Petrolatum ointment containing no active ingredient</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo Topical Ointment</other_name>
    <other_name>Petrolatum</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  65-95 years of age.&#xD;
&#xD;
          -  Good health with all chronic diseases (hypertension, coronary artery disease, etc.)&#xD;
             clinically stable.&#xD;
&#xD;
          -  Selected subjects will be in good health (Per the World Health Organization, good&#xD;
             health will be defined as complete physical, mental, and social well-being and not&#xD;
             merely the absence of disease or infirmity).&#xD;
&#xD;
          -  All diseases or infirmities will be clinically stable whether managed by medications&#xD;
             or not.&#xD;
&#xD;
          -  CLOX score of 10 or greater&#xD;
&#xD;
          -  Women will be postmenopausal&#xD;
&#xD;
          -  Postmenopausal women taking hormone replacement will be included if they have been on&#xD;
             a stable dose for â‰¥6 months&#xD;
&#xD;
          -  Live within a 20 mile drive of the UTHSA campus (7703 Floyd Curl Drive, San Antonio,&#xD;
             TX)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diabetes.&#xD;
&#xD;
          -  History of skin ulcers or poor wound healing, or keloid formers.&#xD;
&#xD;
          -  Smoking.&#xD;
&#xD;
          -  Liver disease.&#xD;
&#xD;
          -  Coumadin anti-coagulation.&#xD;
&#xD;
          -  Treatment with drugs known to affect cytochrome P450 3A (diltiazem, erythromycin, etc.&#xD;
             - due to role in rapamycin metabolism).&#xD;
&#xD;
          -  Treatment with an immunosuppressant (prednisone, etc.) within 6 months.&#xD;
&#xD;
          -  History of recent (within 6 months) Myocardial Infarction or active Coronary Disease.&#xD;
&#xD;
          -  Hypersensitivity to rapamycin or petrolatum (ointment vehicle)&#xD;
&#xD;
          -  Arm tattoos or scars in application area&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ellen Kraig, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas Health at San Antonio</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dean L Kellogg, Jr., MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas Health at San Antonio</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UTHSCSA</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 21, 2020</study_first_submitted>
  <study_first_submitted_qc>October 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 29, 2020</study_first_posted>
  <last_update_submitted>October 1, 2021</last_update_submitted>
  <last_update_submitted_qc>October 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center at San Antonio</investigator_affiliation>
    <investigator_full_name>Ellen Kraig</investigator_full_name>
    <investigator_title>Prof &amp; Deputy Chair of Faculty Development Cell Systems &amp; Anatomy</investigator_title>
  </responsible_party>
  <keyword>Epigenetic clock</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Petrolatum</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Unidentified IPD will be shared in publication form in peer-reviewed journals, at national or international meetings and with collaborating investigators at the PIs home institution.&#xD;
Summary results will be published on ClinicalTrials.gov.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>Data will be shared upon study completion.</ipd_time_frame>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 17, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/48/NCT04608448/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

